Anim-Somuah Millicent, Smyth Rebecca Md, Jones Leanne
Tameside Hospital NHS Foundation Trust, Fountain Street, Ashton-under-Lyne, UK, OL6 9RW.
Cochrane Database Syst Rev. 2011 Dec 7(12):CD000331. doi: 10.1002/14651858.CD000331.pub3.
Epidural analgesia is a central nerve block technique achieved by injection of a local anaesthetic close to the nerves that transmit pain and is widely used as a form of pain relief in labour. However, there are concerns regarding unintended adverse effects on the mother and infant.
To assess the effects of all modalities of epidural analgesia (including combined-spinal-epidural) on the mother and the baby, when compared with non-epidural or no pain relief during labour.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2011).
Randomised controlled trials comparing all modalities of epidural with any form of pain relief not involving regional blockade, or no pain relief in labour.
Two of the review authors independently assessed trials for eligibility, methodological quality and extracted all data. We entered data into RevMan and double checked it for accuracy. Primary analysis was by intention to treat; we conducted subgroup and sensitivity analyses where substantial heterogeneity was evident.
We included 38 studies involving 9658 women; all but five studies compared epidural analgesia with opiates. Epidural analgesia was found to offer better pain relief (mean difference (MD) -3.36, 95% confidence interval (CI) -5.41 to -1.31, three trials, 1166 women); a reduction in the need for additional pain relief (risk ratio (RR) 0.05, 95% CI 0.02 to 0.17, 15 trials, 6019 women); a reduced risk of acidosis (RR 0.80, 95% CI 0.68 to 0.94, seven trials, 3643 women); and a reduced risk of naloxone administration (RR 0.15, 95% CI 0.10 to 0.23, 10 trials, 2645 women). However, epidural analgesia was associated with an increased risk of assisted vaginal birth (RR 1.42, 95% CI 1.28 to 1.57, 23 trials, 7935 women), maternal hypotension (RR 18.23, 95% CI 5.09 to 65.35, eight trials, 2789 women), motor-blockade (RR 31.67, 95% CI 4.33 to 231.51, three trials, 322 women), maternal fever (RR 3.34, 95% CI 2.63 to 4.23, six trials, 2741 women), urinary retention (RR 17.05, 95% CI 4.82 to 60.39, three trials, 283 women), longer second stage of labour (MD 13.66 minutes, 95% CI 6.67 to 20.66, 13 trials, 4233 women), oxytocin administration (RR 1.19, 95% CI 1.03 to 1.39, 13 trials, 5815 women) and an increased risk of caesarean section for fetal distress (RR 1.43, 95% CI 1.03 to 1.97, 11 trials, 4816 women). There was no evidence of a significant difference in the risk of caesarean section overall (RR 1.10, 95% CI 0.97 to 1.25, 27 trials, 8417 women), long-term backache (RR 0.96, 95% CI 0.86 to 1.07, three trials, 1806 women), Apgar score less than seven at five minutes (RR 0.80, 95% CI 0.54 to 1.20, 18 trials, 6898 women), and maternal satisfaction with pain relief (RR 1.31, 95% CI 0.84 to 2.05, seven trials, 2929 women). We found substantial heterogeneity for the following outcomes: pain relief; maternal satisfaction; need for additional means of pain relief; length of second stage of labour; and oxytocin augmentation. This could not be explained by subgroup or sensitivity analyses, where data allowed analysis. No studies reported on rare but potentially serious adverse effects of epidural analgesia.
AUTHORS' CONCLUSIONS: Epidural analgesia appears to be effective in reducing pain during labour. However, women who use this form of pain relief are at increased risk of having an instrumental delivery. Epidural analgesia had no statistically significant impact on the risk of caesarean section, maternal satisfaction with pain relief and long-term backache and did not appear to have an immediate effect on neonatal status as determined by Apgar scores. Further research may be helpful to evaluate rare but potentially severe adverse effects of epidural analgesia on women in labour and long-term neonatal outcomes.
硬膜外镇痛是一种通过在传递疼痛的神经附近注射局部麻醉剂来实现的中枢神经阻滞技术,在分娩中被广泛用作一种缓解疼痛的方式。然而,人们担心其对母婴会产生意外的不良影响。
与分娩期间不进行硬膜外镇痛或不缓解疼痛相比,评估所有硬膜外镇痛方式(包括腰麻 - 硬膜外联合阻滞)对母婴的影响。
我们检索了Cochrane妊娠与分娩组试验注册库(2011年3月31日)。
将所有硬膜外镇痛方式与任何不涉及区域阻滞的疼痛缓解形式或分娩时不缓解疼痛进行比较的随机对照试验。
两位综述作者独立评估试验的纳入资格、方法学质量并提取所有数据。我们将数据录入RevMan并进行准确性的二次核对。主要分析采用意向性分析;在存在明显异质性的情况下,我们进行了亚组分析和敏感性分析。
我们纳入了38项研究,涉及9658名女性;除5项研究外,所有研究均将硬膜外镇痛与阿片类药物进行了比较。结果发现,硬膜外镇痛能提供更好的疼痛缓解效果(平均差(MD)-3.36,95%置信区间(CI)-5.41至-1.31,3项试验,1166名女性);减少额外镇痛措施的需求(风险比(RR)0.05,95%CI 0.02至0.17,15项试验,6019名女性);降低酸中毒风险(RR 0.80,95%CI 0.68至0.94,7项试验,3643名女性);以及降低使用纳洛酮的风险(RR 0.15,95%CI 0.10至0.23,10项试验,2645名女性)。然而,硬膜外镇痛与以下风险增加相关:阴道助产(RR 1.42,95%CI 1.28至1.57,23项试验,7935名女性)、产妇低血压(RR 18.23,95%CI 5.09至65.35,8项试验,2789名女性)、运动阻滞(RR 31.67,95%CI 4.33至231.51,3项试验,322名女性)、产妇发热(RR 3.34,95%CI 2.63至4.23,6项试验,2741名女性)、尿潴留(RR 17.05,95%CI 4.82至60.39,3项试验,283名女性)、第二产程延长(MD 13.66分钟,95%CI 6.67至20.66,13项试验,4233名女性)、使用缩宫素(RR 1.19,95%CI 1.03至1.39,13项试验,5815名女性)以及因胎儿窘迫行剖宫产的风险增加(RR 1.43,95%CI 1.03至1.97,11项试验,4816名女性)。总体剖宫产风险(RR 1.10,95%CI 从0.97至1.25,27项试验,8417名女性)、长期背痛(RR 0.96,95%CI 0.86至1.07,3项试验,1806名女性)在5分钟时阿氏评分低于7分(RR 0.80,95%CI 0.54至1.20,18项试验,6898名女性)以及产妇对疼痛缓解的满意度(RR 1.31,95%CI 0.84至2.05,7项试验,2929名女性)方面,均无证据表明存在显著差异。对于以下结局,我们发现存在显著异质性:疼痛缓解;产妇满意度;额外镇痛措施的需求;第二产程长度;以及缩宫素加强。在数据允许分析的情况下,亚组分析或敏感性分析无法解释这种异质性。没有研究报告硬膜外镇痛罕见但可能严重的不良反应。
硬膜外镇痛似乎能有效减轻分娩期间的疼痛。然而,采用这种镇痛方式的女性进行器械助产的风险增加。硬膜外镇痛对剖宫产风险、产妇对疼痛缓解的满意度和长期背痛无统计学显著影响,且似乎对由阿氏评分确定的新生儿状况无即时影响。进一步的研究可能有助于评估硬膜外镇痛对分娩期女性罕见但可能严重的不良反应以及新生儿长期结局。